Key result
Medical and catheter-based ablation therapies for supraventricular tachycardia require cautious application in special populations like pediatric, pregnant, or congenital heart disease patients.
Highlights the need for caution when applying clinical trial results from usual adult populations to special populations with supraventricular tachycardia.
Clinicians should exercise caution with SVT therapies in special populations; leaves open dedicated trials beyond adult cohorts.
Medical and catheter-based ablation therapies have been successfully applied in treating supraventricular tachycardia, supported by abundant evidences from clinical trials. However, Special populations such as pediatric populations, pregnant patients, or patients with congenital heart diseases are easily excluded from clinical trials; thus, caution is needed when adopting results from clinical trials conducted in the usual adult population.
No takes yet. Share an insight, caveat, or question.
Youngjin Cho (2017) conducted a review in Supraventricular Tachycardia. Medical and catheter-based ablation therapies was evaluated. Medical and catheter-based ablation therapies for supraventricular tachycardia require cautious application in special populations like pediatric, pregnant, or congenital heart disease patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: